MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 52,208 shares, a growth of 171.7% from the April 15th total of 19,213 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 128,113 shares, the days-to-cover ratio is currently 0.4 days.

MDxHealth Trading Down 9.3%

Shares of NASDAQ MDXH opened at $0.89 on Friday. The stock has a market cap of $44.20 million, a P/E ratio of -1.37 and a beta of 1.60. The business’s fifty day simple moving average is $2.42 and its 200-day simple moving average is $3.23. MDxHealth has a 12-month low of $0.68 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. On average, equities analysts forecast that MDxHealth will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. BTIG Research lowered their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a report on Thursday. TD Cowen restated a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday. Lake Street Capital lowered their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Finally, Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MDxHealth currently has a consensus rating of “Moderate Buy” and an average target price of $4.63.

Hedge Funds Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently made changes to their positions in MDXH. GSA Capital Partners LLP purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $48,000. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $53,000. Russell Investments Group Ltd. purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $461,000. Kennedy Capital Management LLC purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $1,826,000. Finally, FreeGulliver LLC boosted its stake in shares of MDxHealth by 104.7% in the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after buying an additional 129,348 shares during the period.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.